secwatch.observer — SEC 8-K summary
======================================

Issuer:     Azenta, Inc. (AZTA)
CIK:        0000933974
Form:       8-K
Filed at:   2026-07-08T12:03:36+00:00
Accession:  0001628280-26-047591
Event type: m_and_a
Sentiment:  positive
Materiality: 0.65
Item codes: 1.01, 2.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Azenta completes sale of B Medical Systems for $63M; $35M vendor loan to buyer
------------------------------------------------------------------------------

- Sale closed July 1, 2026; fixed purchase price $63M: $28M cash at closing, $35M via secured vendor loan.
- Vendor loan from Azenta Germany GmbH to Thelema at 6% interest, matures 3 months from funding date.
- Thelema majority-owned by Luc Provost (Azenta VP & B Medical CEO); Audit Committee approved related-party terms.
- Pro forma balance sheet as of Mar 31, 2026 shows net cash proceeds $19M and $35M note receivable from Thelema.
- Azenta CEO states sale simplifies portfolio and positions company for sustainable growth in core life sciences.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/933974/000162828026047591/0001628280-26-047591-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/933974/000162828026047591/azta-20260701.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-047591

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer